Skip to main content
editor.ajphr@gmail.com
9409046853
e-ISSN: 2321-3647
American Journal of Pharmacy and Health Research

American Journal of Pharmacy and Health Research

LoginTrack Your Paper
Published

Helicobacter Pylori–Associated Peptic Ulcer Disease: Epidemiology, Antimicrobial Resistance, and Future Public-Health Strategies

Published in November 2026 Issue 11 (Vol. 14, Issue 11, 2026)

Helicobacter Pylori–Associated Peptic Ulcer Disease: Epidemiology, Antimicrobial Resistance, and Future Public-Health Strategies - Issue cover

Keywords

Helicobacter pyloriPeptic ulcer diseaseAntimicrobial resistanceEpidemiologyAntimicrobial stewardship

Abstract

Helicobacter pylori remains a significant public health concern because of its association with chronic gastric infection, recurrent peptic ulcer disease (PUD), and increasing antimicrobial resistance (AMR). The review also considers socioeconomic inequalities, diagnostic limitations, and challenges in implementing effective eradication programmes. This narrative review synthesizes current evidence on the global and Indian epidemiology of H. pylori-associated PUD, antimicrobial resistance trends, treatment failures, and their implications for public health and healthcare services. Substantial geographical variation in resistance to metronidazole, clarithromycin, levofloxacin, and amoxicillin, particularly in India, has reduced the effectiveness of several empirical eradication regimens. Effective management requires antimicrobial stewardship, susceptibility-guided therapy, post-treatment confirmation of eradication, and equitable access to reliable diagnostic services. Emerging strategies include molecular resistance testing, vonoprazan-based therapies, adjunctive probiotics, evidence-based investigation of plant-derived antimicrobial compounds, urease inhibitors, and vaccine development. Coordinated clinical, diagnostic, public health, and research efforts are essential to reduce treatment failures, unnecessary antibiotic exposure, and the overall burden of H. pylori infection and associated PUD. Keywords: Helicobacter pylori; Peptic ulcer disease; Antimicrobial resistance; Epidemiology; Antimicrobial stewardship

References

  1. [1]Ren J, Jin X, Li J, Li R, Gao Y, Zhang J, Wang X, Wang G . 2022; The global burden of peptic ulcer disease in 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Int J Epidemiol 51(5):1666-1676. https://doi.org/10.1093/ije/dyac033
  2. [2]Yu Y, Xue J, Lin F, Liu D, Zhang W, Ru S, Jiang F . 2024; Global primary antibiotic resistance rate of Helicobacter pylori in recent 10 years: a systematic review and meta-analysis. Helicobacter 29(3). https://doi.org/10.1111/hel.13103https://doi.org/10.1111/hel.13103
  3. [3]Zou Y, Qian X, Liu X, Song Y, Song C, Wu S, An Y, Yuan R, Wang Y, Xie Y . 2020; The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: a systematic review and meta-analysis. Helicobacter 25(4):e12714. https://doi.org/10.1111/hel.12714
  4. [4]Rocha MC, Gaspar T, Bernardes C, Nunes PP . 2026; Susceptibility-guided versus empirical first-line therapy of Helicobacter pylori infection in adults: a systematic review and meta-analysis. Helicobacter 31(2):e70125. https://doi.org/10.1111/hel.70125
  5. [5]Zhao H, Yan P, Zhang N, Feng L, Chu X, Cui G, Qin Y, Yang C, Wang S, Yang K . 2021; The recurrence rate of Helicobacter pylori in recent 10 years: a systematic review and meta-analysis. Helicobacter 26(6). https://doi.org/10.1111/hel.12852https://doi.org/10.1111/hel.12852
  6. [6]World Health Organization . 2023; Global strategy on infection prevention and control. World Health Organization, Geneva. https://www.who.int/publications/i/item/9789240080515. Accessed 8 Oct 2026
  7. [7]Lin K, Huang L, Wang Y, Li K, Ye Y, Yang S, Li A . 2023; Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: a systematic review and single-arm meta-analysis. Helicobacter 28(6). https://doi.org/10.1111/hel.13015https://doi.org/10.1111/hel.13015
  8. [8]Liu L, Shi H, Shi Y, Wang A, Guo N, Li F, Nahata MC . 2024; Vonoprazan-based therapies versus PPI-based therapies in patients with Helicobacter pylori infection: systematic review and meta-analyses of randomized controlled trials. Helicobacter 29(3). https://doi.org/10.1111/hel.13094https://doi.org/10.1111/hel.13094
  9. [9]Musazadeh V, Nazari A, Faghfouri AH, Emami M, Kavyani Z, Zokaei M et al . 2023; The effectiveness of treatment with probiotics in Helicobacter pylori eradication: results from an umbrella meta-analysis on meta-analyses of randomized controlled trials. Food Funct 14(16):7654-7662. https://doi.org/10.1039/D3FO00300K
  10. [10]Liu Z, Li H, Huang X, Liu Q . 2025; Advances and challenges in Helicobacter pylori subunit vaccine development: antigen candidates and immunization strategies. J Appl Microbiol 136(10):lxaf236. https://doi.org/10.1093/jambio/lxaf236

Authors (1)

TAPAN KUMAR MAHATO

Ranchi College of Pharmacy, Na...

View all publications →

Download Article

PDF

Best for printing and citation

File size: 0.6 MB
Format: PDF
ViewDownload

Summarise this paper with AI:

GoogleGooglePerplexityPerplexityGrokGrokChatGPTChatGPTClaudeClaude

Article Information

Published in:

November 2026 Issue 11 (Vol. 14, Issue 11, 2026)

AJPHR11140003

AJPHR-01-000973

25-42

2026-11-13

JATS XML

Article Impact

Views:2,042
Downloads:1,214

How to Cite

KUMAR MAHATO, T. (2026). Helicobacter Pylori–Associated Peptic Ulcer Disease: Epidemiology, Antimicrobial Resistance, and Future Public-Health Strategies. American Journal of Pharmacy and Health Research, 14(11), 25-42. https://ajphr.com/articles/AJPHR11140003

Article Actions

Whatsapp